cenegermin


( Last Updated : September 2, 2021)
Generic Name:
cenegermin
Project Status:
Pending
Therapeutic Area:
Neurotrophic keratitis
Manufacturer:
Dompé Farmaceutici S.p.A
Call for patient/clinician input open:
Brand Name:
Oxervate
Project Line:
Reimbursement Review
Project Number:
SR0704-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.